AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant
Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.
AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing.
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year